Last C$0.30 CAD
Change Today 0.00 / 0.00%
Volume 0.0
As of 3:18 PM 07/25/14 All times are local (Market data is delayed by at least 15 minutes).

trillium therapeutics inc (TR) Snapshot

Open
C$0.29
Previous Close
C$0.30
Day High
C$0.30
Day Low
C$0.28
52 Week High
03/10/14 - C$0.74
52 Week Low
09/12/13 - C$0.26
Market Cap
36.7M
Average Volume 10 Days
104.7K
EPS TTM
C$-0.10
Shares Outstanding
124.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TRILLIUM THERAPEUTICS INC (TR)

Related News

No related news articles were found.

trillium therapeutics inc (TR) Related Businessweek News

No Related Businessweek News Found

trillium therapeutics inc (TR) Details

Trillium Therapeutics Inc., a biopharmaceutical development company, advances cancer stem cell discoveries into novel and cancer therapies in Canada. Its products comprise Tigecycline, an antibiotic, which is in phase I for study in patients with relapsed or refractory acute myeloid leukemia (AML); SIRPaFc, an antibody-like fusion protein, which is in pre-clinical stage that blocks the activity of CD47, a molecule that is upregulated on cancer stem cells in AML and other tumors; CD200, a human monoclonal antibody that blocks the activity of CD200, an immunosuppressive molecule; and TTI-1612, a recombinant soluble for the treatment of interstitial cystitis (IC), a chronic bladder disease characterized by low urinary HB-EGF levels and a dysfunctional, which recently completed a 28-patient Phase I trial in IC patients. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 and is headquartered in Toronto, Canada.

14 Employees
Last Reported Date: 03/28/14
Founded in 2004

trillium therapeutics inc (TR) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: C$217.5K
Chief Financial Officer
Total Annual Compensation: C$106.0K
Chief Scientific Officer
Total Annual Compensation: C$137.8K
Compensation as of Fiscal Year 2013.

trillium therapeutics inc (TR) Key Developments

Trillium Therapeutics Inc. Presents at Bloom Burton & Co. Healthcare Investor Conference, Jun-18-2014 10:00 AM

Trillium Therapeutics Inc. Presents at Bloom Burton & Co. Healthcare Investor Conference, Jun-18-2014 10:00 AM. Venue: Toronto Board of Trade, 1 First Canadian Place (Corner of Bay and Adelaide), Toronto, ON M5X 1C1, Canada.

Stem Cell Therapeutics Corp. Approves Two Administrative By-Law Resolutions

Stem Cell Therapeutics Corp. announced that at its Annual Shareholders Meeting held on May 27, 2014, shareholders approved the two administrative by-law resolutions.

Stem Cell Therapeutics Corp. has Changed its Name to Trillium Therapeutics Inc

On May 27, 2014, Stem Cell Therapeutics Corp. changed its name to Trillium Therapeutics Inc.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TR:CN C$0.30 CAD 0.00

TR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TR.
View Industry Companies
 

Industry Analysis

TR

Industry Average

Valuation TR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TRILLIUM THERAPEUTICS INC, please visit www.trilliumtherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.